Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Vote in favor of the Web-based Work out schedule to Keep You Fit and Sound - 2Partner of crime boss Steven Lyons arrested in Dubai
- 3'Weezer: The Gathering' 2026 tour: How to get tickets, prices, dates and more
- 4Individual Preparation Administrations to Raise Your Wellness Process
- 5Instructions to Discuss Successfully with Your Auto Collision Lawyer
- California warns of death cap mushrooms outbreak resulting in 3 deaths
- One perk to marrying Richard Marx later in life? 'We don't have time' for stupid arguments, says Daisy Fuentes.
- Australia PM tries to reassure public as panic buying sees fuel demand surge 400% in some regions
- The Effect of Online Organizations on Society: Beating the Difficulties
- UN rights chief says Israeli policy in West Bank 'resembles apartheid system'
- 5 State of the art Advancements in Computer generated Simulation
- What exactly is the Upside Down in 'Stranger Things'? The wormhole revelation, explained.
- 10 Natural products to Remember for Your Eating routine for a Better You
- ‘I love this work, but it’s killing me’: The unique toll of being a spiritual leader today
